Pfizer Inc. (NYSE:PFE) Shares Sold by Twin Capital Management Inc.

Twin Capital Management Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 131,753 shares of the biopharmaceutical company’s stock after selling 3,591 shares during the period. Twin Capital Management Inc.’s holdings in Pfizer were worth $3,793,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Adage Capital Partners GP L.L.C. boosted its stake in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in Pfizer in the 4th quarter worth about $255,000. Brookstone Capital Management increased its stake in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the period. ETF Store Inc. raised its holdings in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares during the last quarter. Finally, KLCM Advisors Inc. raised its holdings in shares of Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PFE. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.6 %

PFE stock traded down $0.15 during mid-day trading on Thursday, hitting $25.27. The stock had a trading volume of 20,581,875 shares, compared to its average volume of 42,262,844. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1-year low of $25.25 and a 1-year high of $40.56. The company has a fifty day moving average of $27.19 and a 200 day moving average of $28.76. The stock has a market capitalization of $143.09 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.14 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.